Physician profile
Christopher John Thomas
NPI 1437739653
$2,635.39
in general payments reported to CMS, 2019-2025
20 companies · $800 in 2025
The $800 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.26 · 2022: $93.39 · 2023: $855 · 2024: $872 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,526.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $550.79 | 2023-2025 | Azstarys |
| Abbvie INC. | $508.77 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $319.88 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Axsome Therapeutics, INC. | $309.80 | 2022-2025 | Auvelity, Sunosi |
| Noven Therapeutics, LLC | $189.35 | 2023-2025 | Xelstrym, Secuado |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.03 | 2023-2025 | Caplyta |
| Imperative Care, INC | $106.25 | 2023-2024 | Zoom 88-T Large Distal Platform |
| Biogen, INC. | $67.45 | 2024 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $63.77 | 2022-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $60.88 | 2023-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $59.71 | 2025 | Spravato |
| Tris Pharma INC | $57.34 | 2023-2024 | Dyanavel Xr |
| Lundbeck LLC | $41.47 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $32.83 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $26.94 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $23.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.98 | 2025 | |
| Neos Therapeutics, LP | $15.26 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.00 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.